Development of a Low-Profile Dual Hormone Patch Pump with Novel Occlusion Sensor
Development of a Low-Profile Dual Hormone Patch Pump with Novel Occlusion Sensor
批准号:
9788425
负责人:
Forrest Payne
金额:
$64.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2021-08-31
关键词:
AdolescentAlgorithmsArtificial PancreasBiocompatible MaterialsBlood GlucoseBluetoothCannulasChildDevelopmentDevicesDoseDrug CarriersDrug ContaminationDrug Delivery SystemsDrug FormulationsDyesElectronicsEnsureEvaluationFDA approvedFailureFamily suidaeFormulationGlucagonGoalsGovernmentGuidelinesHandHormonesHourHypoglycemiaIndividualInsulinInsulin-Dependent Diabetes MellitusLiquid substanceManualsManufacturer NameMeasurementMeasuresMechanicsMethodsPersonsPharmaceutical PreparationsPhasePower SourcesProductionProtocols documentationPumpSafetySeriesSyringesSystemTechniquesTestingUpdateWireless TechnologyWorkbiomaterial compatibilitycostdesignglucose monitorglycemic controlimprovedin vitro testingmanufacturabilitymeetingsmicrofluidic technologynext generationnovelprototyperesponsesensor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Development of a Low-Profile Dual Hormone Patch Pump
with Novel Occlusion Sensor
Project Summary:
The Specific Aim of this project is to develop a discrete, low-profile, dual hormone drug
delivery system using SFC Fluidics’ enabling microfluidic technologies. A DualPump™ will be
developed in which one proprietary ePump® body will independently and accurately deliver both
insulin and glucagon from two separate reservoirs. Latching safety valve sets will independently
and safely control the delivery of each hormone and a dispense confirmation sensor will notify
the user of any dosing errors resulting from occlusions or electrical/mechanical failures. Phase
II will see the integration of all components into an accurate, discrete, low-profile wearable pod,
extensive benchtop testing and initial testing in swine. The end goal of Phase II is production of
a DualPump module that has been introduced to the FDA and is ready to be integrated with all
other components required for a dual hormone artificial pancreas. During Phase IIB, SFC
Fluidics will work with manufacturers of continuous glucose monitors, control algorithms and
stable drug formulations to develop an FDA-approved, robust, and reliable dual hormone
artificial pancreas.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advanced Development of Gemini-DHAP
-
批准号:10760050
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2023
-
负责人:Forrest Payne
-
依托单位:
Development of an Implantable On-Demand Drug Delivery Device for Behavioral Studies in Small Animals
-
批准号:9407379
-
项目类别:
-
资助金额:$75.01万
-
财政年份:2016
-
负责人:Forrest Payne
-
依托单位:
Development of an Implantable On-Demand Drug Delivery Device for Behavioral Studies in Small Animals
-
批准号:9047055
-
项目类别:
-
资助金额:$17.5万
-
财政年份:2015
-
负责人:Forrest Payne
-
依托单位:
海外基金